AAAAl Foundation and David S. Pearlman, MD, FAAAAI Lectureship: Contributing to Discovery and Education (5th year)

Saturday, February 24, 2024
2101 Microbial Influences on Allergic Diseases: Friends and Foes
Convention Center, Level 2, Hall D, 8:15-9:45 AM

Lecturer: Susan Lynch, PhD
Gut Microbiome, Industrialization and the Rise of Chronic Inflammatory Disease

David S. Pearlman, MD, FAAAAI

The AAAAI Foundation is pleased to announce the establishment of the David S. Pearlman, MD FAAAAI Lectureship: Contributing to Discovery and Education. Dr. Pearlman's distinguished career has featured nearly a thousand clinical trials, extensive publishing and outstanding patient care. He is truly a leader in the field.

Dr. Pearlman is a co-founder of Colorado Allergy and Asthma Centers, which today serves over 48,000 patients. Since the clinic's inception in 1972, Dr. Pearlman has been a principal investigator in the Denver Research location, with nearly a thousand clinical Phase I-IV pharmacotherapeutic trials. He has published over 150 articles and texts to inform physicians concerning advances in the field, and is the co-author of three editions of the textbook entitled Allergy, Asthma, and Immunology from Infancy to Adulthood.

Dr. Pearlman has been honored with the American Academy of Allergy, Asthma & Immunology’s Distinguished Clinician Award and has received awards for outstanding contributions to the field of allergy and immunology by the American Board of Pediatrics, University of Colorado Medical School and the Joint Allergy and Asthma Task Force. He has served in leadership positions with the American Board of Allergy and Immunology and the Clinical Research Network.

Dr. Pearlman attended Cornell University and received his Doctor of Medicine from the State University of New York at Syracuse. He went on to train in pediatrics at the University Hospitals of Cleveland and at the University of Colorado Health Sciences Center, where he also had a post-doctoral fellowship in immunology. After a fellowship in pharmacology at the National Institute for Medical Research in London, England, he returned to the University of Colorado Medical School as Director of Pediatric Allergy and Co-Director of the conjoint UCMS/National Jewish/NIH-funded conjoint fellowship in Pediatric Allergy and Immunology.

Dr. Pearlman maintains an academic appointment at the University of Colorado Medical School as a Clinical Professor of Pediatrics. He continues to be active in allergy and asthma research authorships, critical reviews and consulting.
Dr. Lynch’s research focuses primarily on the gut and airway microbiome and chronic inflammatory disease, particularly allergy and asthma. She received her undergraduate and graduate degrees in Microbiology from University College Dublin, Ireland, before completing her postdoctoral training as a Dean’s Fellow in the Department of Microbiology and Immunology at Stanford University. Her research focuses on how the human microbiome promotes immune dysfunction and chronic inflammatory disease. Her studies have led to the identification of specific gut microbial genes that predict risk of disease in childhood and demonstrated that their products promote canonical features of immune dysfunction associated with allergic inflammatory disease development. She has served on a National Academy of Science and Engineering committee and as an American Society of Microbiology, Distinguished Lecturer. She has been awarded the Rebecca Buckley Lectureship from theAAAAI, named as one of Foreign Policy Magazine’s "Global Thinkers" and was awarded the Odell Lecture from the University of Wisconsin. She founded the Microbiome Research Core at the University of California San Francisco, is the Associate Director of the Microbiome in Inflammatory Bowel Disease Research Program, serves on the executive committee of ImmunoX and the Precision Medicine initiative at UCSF and is the Director of the UCSF Benioff Center for Microbiome Medicine. She also co-founded Siolta Therapeutics Inc., a biotech company whose lead microbial live biotherapeutic for the prevention of childhood atopy and asthma is currently in human trials.